Objectives:

" Enhance pharmaceutical manufacturers* understanding of regulatory expectations and best practices for the scientific assessment of tablet subdivision.

• Clarify current guidelines, compliance requirements, and the scientific principles that support robust subdivision evaluation.

* Ensure product quality, safeguard patient safety, and facilitate successful regulatory approval through effective subdivision assessment practices.